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Pancreatic cancer is the fifth leading cause of cancer death in the United States. Nearly every person diagnosed
with pancreatic cancer will die from it, usually in !6 mo. Familial clustering of pancreatic cancers is commonly
recognized, with an autosomal dominant inheritance pattern in ∼10% of all cases. However, the late age at disease
onset and rapid demise of affected individuals markedly hamper collection of biological samples. We report a genetic
linkage scan of family X with an autosomal dominant pancreatic cancer with early onset and high penetrance. For
the study of this family, we have developed an endoscopic surveillance program that allows the early detection of
cancer and its precursor, before family members have died of the disease. In a genomewide screening of 373
microsatellite markers, we found significant linkage (maximum LOD score 4.56 in two-point analysis and 5.36 in
three-point analysis) on chromosome 4q32-34, providing evidence for a major locus for pancreatic cancer.
Adenocarcinoma of the pancreas typifies the most
dreaded of all cancers, because it is difficult to detect,
early to metastasize, and resistant to treatment (Schnall
and Macdonald 1996). Of the estimated 29,200 new
cases currently diagnosed in the United States each year,
28,900 will die of the disease, usually !4–6 mo after
diagnosis. Although pancreatic cancer is relatively com-
mon, very few dominant genetic or environmental risk
factors have been identified (Kernan et al. 1999). There
is, however, growing epidemiological evidence for im-
portant genetic susceptibility factors (Silverman et al.
1999; Tersmette et al. 2001). In addition, familial and
Received November 16, 2001; accepted for publication January 10,
2002; electronically published February 27, 2002.
Address for correspondence and reprints: Dr. Teresa A. Brentnall,
University of Washington Medical Center, Box 356424, 1959 N.E.
Pacific, Seattle, WA 98195. E-mail: teribr@u.washington.edu; or Dr.
David C. Whitcomb, University of Pittsburgh, 571 Scaife Hall, 3550
Terrace Street, Pittsburgh, PA 15261. E-mail: whitcomb@pitt.edu
* The first two authors contributed equally to this study.
† Present affiliation: Department of Gastroenterology, Hepatology
and Infectious Diseases, University of Heidelberg atMannheim,Mann-
heim, Germany.
‡ The last three authors codirected this study.
 2002 by The American Society of Human Genetics. All rights reserved.
0002-9297/2002/7004-0025$15.00
inherited pancreatic cancer syndromesmay provide clues
to pancreatic cancer susceptibility (Lynch et al. 1990;
Banke et al. 2000; Efthimiou et al. 2001; Rulyak and
Brentnall 2001; Tersmette et al. 2001; Whitcomb et al.
2001).
Several familial cancer syndromes increase the risk of
pancreatic cancer. The best-characterized include the he-
reditary nonpolyposis-colon-cancer syndrome (HNPCC
[MIM 114500]) associated with mutations mainly on
chromosomes 2 and 3, hereditary breast-ovarian cancer
syndrome (BRCA2 [MIM 600185]) associated with the
BRCA2 gene mutations on chromosome 13q, Peutz-
Jeghers polyposis with mutations in the serine/threonine
protein kinase 11 (STK11 [MIM 602216]) on chro-
mosome 19p, and familial atypical multiple-mole-mel-
anoma syndrome (FAMMM [MIM 600160]) with mu-
tations on chromosome 9p (Efthimiou et al. 2001;
Rulyak and Brentnall 2001; Whitcomb et al. 2001). In
general, these syndromes increase the risk of pancreatic
cancer ∼10-fold, although the risk of pancreatic cancer
in FAMMM may be higher. Another hereditary predis-
position to pancreatic cancer results from the gain-of-
function protease serine-1 (PRSS1 [MIM 276000]) gene
mutations associated with hereditary pancreatitis (Whit-
comb et al. 1996; Whitcomb 1999, 2000). Individuals
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Figure 1 Pedigree of family X. Blackened symbols denote affected family members. The “X” marks where the pedigree was split for
GENEHUNTER analysis.
affected with pancreatitis have a lifetime pancreatic-can-
cer risk ratio of 57 and cumulative incidence, to age 70
years, of 40% (Lowenfels et al. 1997). However, the
critical PRSS1-gene mutations are rare, and PRSS1 is a
digestive enzyme causing childhood-onset pancreatitis,
with cancer developing decades later, probably because
of the environment of chronic pancreatic inflammation
(Whitcomb 2000; Ponder 2001).
Many familial-pancreatic-cancer kindreds have been
identified, most notably the family of the former Presi-
dent of the United States, Jimmy Carter (Lynch et al.
1990; Brentnall et al. 1999; Banke et al. 2000; Hruban
et al. 2001). These families inherit pancreatic cancer in
the absence of other types of cancer (colon, breast, mel-
anoma, etc.) and in the absence of chronic pancreatitis.
However, the late age at onset (60–70 years), unknown
penetrance, absence of recognized premalignant phe-
notype, and short survival (average 6 mo) after the di-
agnosis of pancreatic cancer have made genetic linkage
analyses nearly impossible.
Families with pancreatic cancer are relatively uncom-
mon, and some groupings of pancreatic cancers within
a family are likely due to chance. However, recent seg-
regation analysis suggests that 10% of patients with
pancreatic cancer inherit the risk of pancreatic cancer in
an autosomal dominant pattern (Banke et al. 2000). The
most striking example is “family X” (fig. 1), which we
have described elsewhere (Brentnall et al. 1999; Meckler
et al. 2001). The primary characteristics include early
age at onset (median age 43 years) and high penetrance
(i.e., 180%) of pancreatic cancer. Moreover, some, but
not all, family members can develop pancreatic insuf-
ficiency prior to the onset of cancer. We have been able
to develop a surveillance program in this and other kin-
dreds with familial pancreatic cancer, using endoscopic
ultrasound and endoscopic retrograde pancreatography
to help identify patients with precancerous changes. All
of the precancerous changes (dysplasia) are verified his-
tologically. The early identification of cancer/precancer
through surveillance, the large family size, and the high
level of family-member participation in family X enabled
the first successful pancreatic-cancer genetic linkage
study to be performed.
The study was performed according to approved In-
stitutional Review Board guidelines at the University of
Washington. The cancer in family X can be associated
with a prodrome of pancreatic endocrine and/or exo-
crine insufficiency, possibly due to the increasing meta-
plastic and dysplastic changes in the pancreas. The pro-
drome of pancreatic insufficiency has also been described
in some patients with sporadic pancreatic cancer (Sil-
verman et al. 1999). No other types of cancer or dis-
tinctive features are notable in family X. Family mem-
bers were considered affected if they had histologic
evidence of either cancer or dysplasia (precancer) or if
there were records (medical or death certificate) docu-
menting pancreatic cancer. Family members who had the
prodrome of pancreatic insufficiency but for whom fur-
ther histologic confirmation was lackingwere considered
to be affected also. There are 20 cases, in four genera-
tions (fig. 1), of either dysplasia/cancer ( ) or, innp 18
lieu of histologic diagnosis ( ), the phenotypic pro-np 2
drome equivalent. All of the affected family members
from generations II and III had either pancreatic cancer
or histologic evidence of pancreatic dysplasia; in gen-
eration IV, two members had evidence of pancreatic in-
sufficiency (phenotypic prodrome), and two others had
histologic evidence of pancreatic dysplasia. Blood from
all living individuals was obtained, and DNA was ex-
tracted. Genetic material from pathology specimens was
obtained from three deceased individuals, and the DNA
was recovered by standard deparaffinization techniques.
The study subjects were initially genotyped at 373
marker loci, by the ABI PRISM Linkage Mapping Set
Version 2 (Applied Biosystems). Up to 12 PCR products
from single DNA samples were pooled together, heat
denatured, and loaded into ABI 377 DNA Sequencers
(Applied Biosystems), for GENESCAN data collection.
The data were analyzed and the alleles were assigned by
either TrueAllele software (Cybergenetics) or Genotyper
2.5 (Applied Biosystems). The genetic spacing between
the markers averaged 9.4 cM, according to comprehen-
sive genetic maps of microsatellite loci (Broman et al.
1998). The data were checked for Mendelian inconsis-
tencies, by the PedCheck program, which uses the in-
dividual’s genotype information to check for parent-
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Figure 2 LOD scores for multipoint analysis
Table 1
Two-Point LOD Scores for Various v Values
MARKER
LOD SCORE AT v p
aˆv
MAXIMUM
LOD SCORE.00 .01 .05 .10 .20 .30 .40
D4S413 1.18 1.15 1.02 .86 .54 .24 .05 .00 1.18
D4S393 4.02 3.95 3.66 3.30 2.53 1.67 .75 .00 4.02
D4S1603 2.30 2.25 2.06 1.81 1.31 .81 .35 .00 2.30
D4S2952 3.62 3.55 3.24 2.85 2.01 1.15 .37 .00 3.62
D4S1566 .98 .95 .84 .71 .46 .24 .07 .00 .98
D4S620 .97 .95 .88 .78 .57 .37 .18 .00 .97
D4S1596 1.13 1.09 .97 .81 .51 .23 .05 .00 1.13
D4S2979  4.95 1.75 .62 .10 .17 .06 .27 .18
D4S1597 3.72 3.64 3.31 2.88 1.99 1.11 .36 .00 3.72
D4S2910 1.15 1.11 .98 .83 .54 .28 .08 .00 1.15
D4S1545  .38 .91 .98 .82 .52 .20 .10 .98
D4S1617 2.92 2.87 2.66 2.36 1.72 1.06 .45 .00 2.92
D4S621  1.40 1.85 1.82 1.42 .88 .36 .07 1.87
D4S1595 4.16 4.08 3.74 3.30 2.39 1.46 .60 .00 4.16
D4S2991 2.33 2.27 2.07 1.82 1.31 .80 .33 .00 2.33
D4S2977  2.43 2.80 2.67 2.08 1.32 .51 .05 2.80
D4S1539  .17 .67 .73 .54 .27 .08 .09 .73
D4S1555  .25 .79 .88 .74 .46 .17 .10 .88
D4S3028  2.68 3.04 2.89 2.25 1.44 .60 .05 3.04
D4S3030 4.56 4.47 4.12 3.67 2.70 1.68 .67 .00 4.56
D4S415  .73 .14 .02 .07 .05 .03 .19 .07
a is the v at which the maximum LOD score is obtained.ˆv
child inconsistencies and too many alleles in a sibship
and then uses genotype elimination to find more-subtle
errors (O’Connell and Weeks 1998). Two-point and
three-point analyses were performed by FASTLINK
(Schaffer et al. 1994). Multipoint analysis and haplotype
analyses were performed byGENEHUNTER version 2.1
(Markianos et al. 2001). Because of the size of this ped-
igree, the family was split into two subpedigrees, for
calculation of LOD scores by GENEHUNTER.
We performed a genome scan of family X, with 373
microsatellite markers (average spacing 9.4 cM). Of the
373 markers, 6 showed LOD scores 11 in two-point link-
age analysis. These six markers were located on chro-
mosome 3 (two markers), chromosome 4 (two markers),
chromosome 7 (one marker), and chromosome 14 (one
marker). Markers D3S1278 and D3S1267 were adjacent
to each other and were separated by 9.3 cM, and markers
D4S1597 and D4S1539 were adjacent to each other and
were separated by 12 cM. Two additional markers flank-
ing the positive markers on chromosome 4 also gave pos-
itive LOD scores. The four chromosome 4 markers were
the only contiguous set of fourmarkerswith positiveLOD
scores in the scan. All genomic regions where two con-
secutive markers gave positive LOD scores were followed
up with three-point analysis. Each of these analyses re-
sulted in LOD scores !1.5, except on chromosome 4,
where consecutive pairs D4S413, D4S1597, D4S1539,
and D4S415 gave LOD scores 12.1 and where markers
D4S1597 and D4S1539, and the interval between them,
showed LOD scores of ∼3.0.
On the basis of these analyses, we determined that the
D4S413–D4S415 interval was the most likely location
of the disease gene. We genotyped 17 additional markers
within this interval and included additional family mem-
bers in the analysis. Two-point analyses of these addi-
tional markers provided further support for localization
of the gene to this region (table 1). The highest LOD
score was 4.56 at a recombination fraction (v) of 0, for
D4S3030. In three-point analysis, the maximum LOD
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score increased to 5.36, between markers D4S1595 and
D4S2991.
In multipoint analysis, the maximum LOD score was
4.9, at D4S2952/D4S1566, and the 2-LOD support in-
terval extended from D4S413 to D4S1596 (fig. 2). Hap-
lotype analysis showed that a single haplotype is, in
general, present in all of the affected individuals and
is absent in the unaffected individuals. Crossovers in-
dicate that the gene lies between markers D4S413 and
D4S2910, consistent with the multipoint analysis.
The new pancreatic cancer–susceptibility locus iden-
tified in the present study appears to encompass the first
pancreatic cancer–specific genetic defect. All of the
known pancreatic cancer–associated genes and cancer
syndromes have been excluded by localization of the
susceptibility gene to chromosome 4q32-34. Further-
more, the autosomal dominant inheritance pattern ar-
gues against the hypothesis that this syndrome is poly-
genic. Other inherited-cancer syndromes usually involve
alteration of a rate-limiting event needed for the devel-
opment of cancer (e.g., the Rb gene in retinoblastoma),
defective DNA repair, or genomic instability (Knudson
1971; Cavenee et al. 1983; Ponder 2001). Thus, the
chromosome 4q32-34 region appears to represent a
unique pancreatic cancer–specific locus.
Affected family members develop metastatic pancre-
atic adenocarcinoma that is histologically identical to
sporadic pancreatic cancer (Brentnall et al. 1999; Meck-
ler et al. 2001). Histologic review reveals that dysplasia
(precancer) involves the small- and medium-size ducts.
The dysplasia can be widespread—but it is not uniform,
although the underlying fibrocystic change is. These
histologic findings raise the possibility that the gene
may involve a pathway associated with the desmoplas-
tic reaction common in pancreatic cancer. Some late-
stage–affected members of family X have developedmul-
tiple types of pancreatic cancer within a single organ.
Ductal adenocarcinoma is always present, but, occa-
sionally, small-cell undifferentiated carcinoma, anaplas-
tic giant carcinoma, and/or cystadenocarcinoma may
accompany it. Such tumor heterogeneity suggests the
possibility of unregulated growth of either pancreat-
ic stem cells or a mutator phenotype. The precursor
changes of widespread fibrosis and multifocal dysplasia,
together with the very-late-stage tumor heterogeneity,
may reflect a common genetic pathway associated with
this pancreatic cancer–susceptibility gene on chromo-
some 4q.
We have studied 28 families that inherit pancreatic can-
cer (authors’ unpublished data). Although family X is the
largest of the kindreds, it is not unique. There are other
families that have high penetrance, inheriting pancreatic
cancer in an autosomal fashion—these families are, in
general, smaller than family X. There appears to be some
variety in the phenotypic presentation in families with
familial pancreatic cancer: some kindreds have pancreatic
insufficiency prior to cancer onset, whereas others do not;
and some families, like family X, have anticipation (earlier
onset of cancer in each succeeding generation), whereas
other families do not. Whether the current loci are as-
sociatedwith susceptibility to pancreatic cancer in all fam-
ilies with familial pancreatic cancer remains to be de-
termined. Indeed, familial pancreatic cancer may be a
heterogeneous disorder, with separate genes causing sim-
ilar, but not identical, phenotypes—just as is the case
in hereditary breast cancer syndromes BRCA1 (MIM
113705 and BRCA2, respectively).
The availability of BACs and ESTs that map to the
4q32-34 region will greatly facilitate the localization of
the gene. With the use of these tools, we will be able to
identify regions of 4q32-34 that show allelic loss or gain,
as well as changes in gene expression during tumor de-
velopment. We have constructed an array of all of the
ESTs that map to this region, we are currently analyzing
the expression pattern, andwe are screening patient sam-
ples, for allelic loss, with the BAC clones that map to
the area. This information will aid in the identification
of the mutant gene in this family.
Progress in understanding and treating pancreatic can-
cer has been slow (Kern et al. 2001). The identification
of a susceptibility gene on chromosome 4q should shed
new light on the mysteries that surround pancreatic can-
cer. By understanding the identity of the gene, it is pos-
sible to fully understand the underlying mechanism and
the possibilities for intervention. The discovery of a gene
for familial pancreatic cancer would also allow identi-
fication of affected families—and thus help tailor sur-
veillance methods to those who are at highest risk (e.g.,
gene carriers). As with the familial adenomatous-poly-
posis paradigm of colon cancer, it is possible that the
gene causing the familial form pancreatic cancer plays
an important role in the sporadic form of the disease.
Finally, understanding the function of the gene may be
the cornerstone for chemoprevention efforts.
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